Nsaids    (DrugBank: -)

4 diseases
告示番号疾患名(ページ内リンク)臨床試験数
46悪性関節リウマチ9
70広範脊柱管狭窄症3
107若年性特発性関節炎[全身型若年性特発性関節炎(~2018.3)]2
271強直性脊椎炎11

46. 悪性関節リウマチ [臨床試験数:4,183,薬物数:2,538(DrugBank:401),標的遺伝子数:183,標的パスウェイ数:219
Searched query = "Malignant rheumatoid arthritis", "Rheumatoid arthritis", "Rheumatoid arthritis with vasculitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
9 / 4,183 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR2000033004
2020-06-012020-05-17Clinical study of intravenous lidocaine infusion in patients with rheumatoid arthritisClinical study of intravenous lidocaine infusion in patients with rheumatoid arthritis Rheumatoid arthritisGroup 1:glucocorticoid;Group 2:intravenous lidocaine infusion and glucocorticoid;Group 3:intravenous lidocaine infusion;Group 4:NSAIDS;Department of Pain, Guizhou Provincial People's HospitaNULLPending1865BothGroup 1:30;Group 2:30;Group 3:30;Group 4:30;China
2NCT03699293
(ClinicalTrials.gov)
September 22, 201821/9/2018NSAIDs vs. Coxibs in the Presence of AspirinNSAIDs vs. Coxibs in the Presence of Aspirin: Effects on Platelet Function, Endothelial Function, and Biomarkers of Inflammation in Subjects With Rheumatoid Arthritis and Increased Cardiovascular Risk or Cardiovascular DiseaseRheumatoid Arthritis;Cardiovascular DiseasesDrug: celecoxib 200mg capsule;Drug: naproxen sodium 550mg tablet;Drug: Aspirin 81mg tabletInova Health Care ServicesNULLUnknown status18 Years75 YearsAll30Phase 4United States
3NCT03112213
(ClinicalTrials.gov)
January 12, 201710/4/2017Characterization of Non-Steroidal Anti-Inflammatory Drug (NSAID) Intake in Rheumatoid Arthritis (RA) Participants on Tocilizumab (RoACTEMRA®) TreatmentCONIFER (Characterization of NSAID Intake for Established Rheumatoid Arthritis)Rheumatoid ArthritisDrug: Tocilizumab;Drug: NSAIDsHoffmann-La RocheNULLCompleted18 YearsN/AAll135Germany
4NCT02878161
(ClinicalTrials.gov)
January 201612/7/2016Predictability Studies on the Efficacy of TNF-a Inhibitors in Chinese RA From Real WorldScreening Protein Predictive of Response to Tumor Necrosis Factor-a Inhibitors Treatment in Chinese Rheumatoid Arthritis From Real World and Investigating Its Mechanism Through Signal PathwayRheumatoid ArthritisDrug: methotrexate(necessary);Biological: infliximab;Biological: etanercept;Biological: adalimumab;Drug: leflunomide (permitted, not necessary);Drug: NSAIDs (permitted,not necessary);Drug: Glucocorticoids (permitted,not necessary)Fen LiNULLEnrolling by invitation18 Years75 YearsBoth240Phase 4NULL
5ChiCTR-TRC-14004520
2014-05-012014-04-13To study the signal pathways of Rheumatoid Arthritis Syndrome of Accumulated Dampness and intervention mechanism of Sanhuang Yilong Decoction based the theory that lung, spleen and kidney regulate waterTo study the signal pathways of Rheumatoid Arthritis Syndrome of Accumulated Dampness and intervention mechanism of Sanhuang Yilong Decoction based the theory that lung, spleen and kidney regulate water metabolism rheumatoid arthritistwo:Methotrexate, hydroxychloroquine sulfate pills and NSAIDs in both groups; Sanhuang Yinong decoction will be give in the experimental group;RA patients:NA;General Hospital of Chengdu Military RegionNULLRecruiting4565Bothtwo:240;RA patients:40;I (Phase 1 study)China
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6JPRN-UMIN000005362
2011/04/0101/04/2011Clinical study for the efficacy of mesalazine for the treatment of small bowel injury caused by non-steroidal anti-inflammatory drugs(NSAIDs). Patients with rheumatoid arthritis with anemia taking NSAIDsTreatment with mesalazineDepartment of Gastroenterology and Hepatology, Osaka University Graduate School of MedicineNULLComplete: follow-up complete20years-old70years-oldMale and Female13Not selectedJapan
7JPRN-UMIN000004271
2009/04/0127/09/2010Upper gastrointestinal endoscopic findings in Japanese with rheumatoid arthritis (RA) receiving long-term NSAIDs therapy, and the usefulness of switching to selective COX-2 inhibitor celecoxib Rheumatoid arthritis (RA)NSAIDs-induced gastrointestinal mucosal injuryJapanese rheumatic patients who have been treated with NSAIDs for twelve or more weeks are switched to CEL (400mg/day). Upper GI endoscopy is conducted before and after administration of CEL. Patients with ulcers at the enrollment are switched to CEL (400mg/day) with famotidine (20mg/day) after healing of their pre-existing ulcers following treatment.Hoshigaoka Koseinenkin HospitalNULLComplete: follow-up complete20years-oldNot applicableMale and Female100Not applicableJapan
8NCT00595517
(ClinicalTrials.gov)
October 20077/1/2008Long Term Study to Investigate the Efficacy & Safety of D961H (Esomeprazole) for the Prevention of NSAIDs-induced UlcerA Long Term Study to Investigate the Efficacy and Safety Study of D961H (Esomeprazole) (20 mg Once Daily) for the Prevention of Gastric and/or Duodenal Ulcers Associated With Daily Nonsteroidal Anti-inflammatory Drug (NSAID) UseGastric Ulcer;Duodenal Ulcer;Rheumatoid Arthritis;Osteoarthritis;LumbagoDrug: Esomeprazole 20 mgAstraZenecaNULLCompleted20 YearsN/AAll395Phase 3Japan
9NCT02180516
(ClinicalTrials.gov)
October 20011/7/2014Safety and Efficacy of Meloxicam Compared to Other Nonsteroidal Antiinflammatory Drugs (NSAIDs) in an Observational Cohort Study of Patients With Rheumatoid Arthritis, Osteoarthritis, Lumbago, Scapulohumeral Periarthritis, Neck, Shoulder and Arm SyndromeSafety and Efficacy of Meloxicam (MOBIC) Compared to Other NSAIDs in Approved Therapeutic Dosages and Routes of Administration in an Observational Cohort Study of Patients With Rheumatoid Arthritis, Osteoarthritis, Lumbago, Scapulohumeral Periarthritis, Neck, Shoulder and Arm SyndromeArthritis, RheumatoidDrug: Meloxicam;Drug: Other Non Steroidal Anti-Inflammatory Drugs (NSAIDs) except etodolacBoehringer IngelheimNULLCompletedN/AN/ABoth9984N/ANULL

70. 広範脊柱管狭窄症 [臨床試験数:91,薬物数:195(DrugBank:54),標的遺伝子数:60,標的パスウェイ数:85
Searched query = "Spinal stenosis", "Extensive spinal canal stenosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 91 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-jRCTs021200007
19/06/202003/06/2020MiroTASEfficacy and Safety of Mirogabalin for the Treatment as Add-On to NSAIDs in patients with Peripheral Neuropathic Pain caused by Lumbar Spinal Stenosis : Multi-institutional, randomized, open, parallel-design and interventional Study Lumber Spiral StenosisComparison in the effect and safety of Mirogabalin add-on therapy to NSAIDs and NSAIDs monotherapy for patients with Lumber Spiral Stenosis and administrated of NSAIDs.
1) NSAIDs monotherapy as a study drug are prescribed in accordance with a package insert and each of their administration and dosage is not changed while a study drug is administrated.
2) Mirogabalin add-on therapy to NSAIDs: NSAIDS as a study drug are prescribed in accordance with a package insert and each of their administration and dosage is not changed while a study drug is administrated. Mirogabalin is prescribed as follows in accordance with renal function of a subject.
Patients with creatinine clearance more than 60mL/min: Mirogabalin is administrated in dose of 5mg twice a day at the first week. At the next week, Mirogabalin is administrated in dose of 10mg twice a day. At week 5(after Visit3), dose of Milogabalin is increased to 15mg twice a day unless there is no problem with the safety. After that, the dose of Mirogabalin is controlled by 10mg twice a day or 15mg twice a day depending on safety findings.
Patients with creatinine clearance 30-60mL/min: Mirogabalin is administrated in dose of 2.5mg twice a day at the first week. At the next week, Mirogabalin is administrated in dose of 5mg twice a day. At week 5(after Visit3), dose of Milogabalin is increased to 7.5mg twice a day unless there is no problem with the safety. After that, the dose of Mirogabalin is controlled by 5mg twice a day or 7.5mg twice a day depending on safety findings.
Also, more than 7 days washout period before enrollment is required for target patients administrated of prohibited drugs.
If the administration of Mirogabalin is discontinued, down-titration is needed in accordance with the insert package.
Nikaido TakuyaDaiichi Sankyo Co., LtdRecruiting>= 20age oldNot applicableBoth300N/AJapan
2NCT01943435
(ClinicalTrials.gov)
November 20, 20138/9/2013Study Comparing 3 Different Treatments for Arthritis of the Lower Back (Lumbar Spinal Stenosis)A Comparison of Non-Surgical Treatment Methods for Patients With Lumbar Spinal StenosisLumbar Spinal StenosisDrug: NSAIDs; adjunctive analgesics; adjunctive anti-depressants;Procedure: Lumbar epidural injection;Other: Joint Mobilizations (spine, sacroiliac, hip);Other: Individualized exercises: clinical setting;Other: Group Exercise: community settingMichael Schneider, DC, PhDPatient-Centered Outcomes Research InstituteCompleted60 YearsN/AAll259N/AUnited States
3JPRN-UMIN000005382
2010/12/0105/04/2011Intraoperative perineural infiltration of ropivacaine for acute postlaminectomy pain lumbar spinal stenosisGeneral anesthesia and NSAIDs.
As a contorol,saline 10ml infiltrate per one interspinal segment.
Generalanesthesia and NSAIDs.
0.2%ropivacaine 10ml infiltrate per one interspinal segment.
General anesthesia and NSAIDs.
From catheter in injury part,administration of 0.2%ropivacaine 6ml/h.
Duration of administration:2 days after the operation.
Higashi Ohmiya general hospitalNULLComplete: follow-up complete20years-old75years-oldMale and Female60Not selectedJapan

107. 若年性特発性関節炎[全身型若年性特発性関節炎(~2018.3)] [臨床試験数:151,薬物数:75(DrugBank:13),標的遺伝子数:16,標的パスウェイ数:90
Searched query = "Juvenile idiopathic arthritis [Systemic juvenile idiopathic arthritis (~Mar 2018)]", "Systemic-onset juvenile idiopathic arthritis", "JIA", "SJIA"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 151 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03301883
(ClinicalTrials.gov)
April 26, 201821/9/2017A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA)A Phase IV, Multicenter, Single-Arm, Open-Label Study to Assess the Efficacy and Safety of Tocilizumab in Chinese Patients With Systemic Juvenile Idiopathic ArthritisJuvenile Idiopathic ArthritisDrug: Tocilizumab;Drug: NSAIDs;Drug: CSs;Drug: MTXHoffmann-La RocheNULLRecruiting2 Years17 YearsAll74Phase 4China
2NCT00642460
(ClinicalTrials.gov)
May 200819/3/2008A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA)A Randomized, Placebo-controlled Study to Evaluate the Effect of Tocilizumab on Disease Response in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA), With an Open-label Extension to Examine the Long Term Use of TocilizumabJuvenile Idiopathic ArthritisDrug: tocilizumab [RoActemra/Actemra];Drug: Placebo;Drug: Non-steroidal anti-inflammatory drugs (NSAIDs);Drug: methotrexate;Drug: corticosteroidsHoffmann-La RocheNULLCompleted2 Years17 YearsAll112Phase 3United States;Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;France

271. 強直性脊椎炎 [臨床試験数:531,薬物数:343(DrugBank:66),標的遺伝子数:41,標的パスウェイ数:141
Searched query = "Ankylosing spondylitis", "Spondylarthritis ankylopoietica"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
11 / 531 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02758782
(ClinicalTrials.gov)
September 201620/4/2016NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of Structural Damage in Ankylosing SpondylitisCOmparison of the Effect of Treatment With NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of StrUctural Damage in the Spine Over Two Years in Patients With ankyLosing Spondylitis: a Randomized Controlled Multicentre TrialAnkylosing SpondylitisBiological: Golimumab;Drug: CelecoxibCharite University, Berlin, GermanyNULLUnknown status18 YearsN/AAll156Phase 4Germany
2EUCTR2016-000615-33-DE
(EUCTR)
29/07/201606/07/2016Comparison of the effect of treatment with NSAIDs added to anti-TNF therapy versus anti-TNF therapy alone on progression of structural damage in the spine over two years in patients with ankylosing spondylitis: a randomized controlled multicentre trial (CONSUL)Comparison of the effect of treatment with NSAIDs added to anti-TNF therapy versus anti-TNF therapy alone on progression of structural damage in the spine over two years in patients with ankylosing spondylitis: a randomized controlled multicentre trial (CONSUL) - CONSUL ankylosing spondylitis (AS)
MedDRA version: 21.1;Level: LLT;Classification code 10041672;Term: Spondylitis ankylosing;System Organ Class: 100000004859
MedDRA version: 21.1;Classification code 10048398;Term: Spondylitis ankylosing aggravated;System Organ Class: 100000004859
MedDRA version: 20.0;Classification code 10002557;Term: Ankylosing spondylitis and other inflammatory spondylopathies;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Trade Name: Simponi
Trade Name: Celebrex
Charite UniversitaetsmedizinNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
170Phase 4Germany
3NCT02469753
(ClinicalTrials.gov)
October 23, 20159/6/2015Interest of Continuous Non-Steroidal Anti-Inflammatory Drug Treatment in Ankylosing Spondylitis Patients Treated by Anti-TNF Therapy in the Prevention of Radiographic OutcomesInterest of Continuous Non-Steroidal Anti-Inflammatory Drug Treatment in Ankylosing Spondylitis Patients Treated by Anti-TNF Therapy in the Prevention of Radiographic OutcomesAnkylosing SpondylitisDrug: NSAIDs;Drug: anti-TNFUniversity Hospital, BordeauxNULLRecruiting18 YearsN/AAll225Phase 3France;Monaco
4NCT02293681
(ClinicalTrials.gov)
April 10, 201514/11/2014An Observational Study of Infliximab in Participants Suffering From Ankylosing Spondylitis With Hip InvolvementA Multicenter and Observational Study to Assess the Effectiveness of Infliximab Comparing With Conventional Therapy in Ankylosing Spondylitis Subjects With Hip InvolvementSpondylitis, AnkylosingDrug: Infliximab;Drug: NSAIDs;Drug: DMARDsJanssen Research & Development, LLCNULLTerminated16 Years40 YearsAll76N/AChina
5NCT01091675
(ClinicalTrials.gov)
September 201022/3/2010Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis and Inadequate Response to =2 NSAIDsAssessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis (AS) and Inadequate Response to =2 Nonsteroidal Antiinflammatory Drug (NSAID)Ankylosing SpondylitisDrug: EtoricoxibSpanish Foundation of RheumatologyNULLCompleted18 YearsN/AAll58Phase 3Spain
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT01209702
(ClinicalTrials.gov)
September 201024/9/2010A Study of RoActemra/Actemra (Tocilizumab) in Patients With Ankylosing Spondylitis Who Have Failed Treatment With NSAIDsA Ph II/III Seamless, Multi-center, Randomized, Double-blind, Placebo-controlled Study of the Reduction in Signs and Symptoms and Inhibition of Structural Damage During Treatment With Tocilizumab Versus Placebo in Patients With Ankylosing Spondylitis Who Have Failed Non-steroidal Anti-inflammatory Drugs and Are naïve to TNF Antagonist Therapy NSAIDsSpondylitis, AnkylosingBiological: tocilizumab;Drug: PlaceboHoffmann-La RocheNULLTerminated18 YearsN/AAll306Phase 3United States;Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;India;Italy;Lithuania;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom;Mexico;Netherlands
7NCT02456363
(ClinicalTrials.gov)
November 200914/12/2014Anti-Tumor Necrosis Factor Therapy In Patients With Ankylosing SpondylitisAnti-Tumor Necrosis Factor Therapy In Patients With Ankylosing Spondylitis—A Registry ProjectAnkylosing SpondylitisBiological: TNF alpha;Drug: NSAIDs and sulfasalazineChung Shan Medical UniversityNULLRecruiting18 YearsN/ABoth300Phase 2Taiwan
8NCT01077843
(ClinicalTrials.gov)
August 17, 200926/2/2010Post-authorization Safety Study of Etoricoxib and Other Anti-inflammatory Therapies in European Patients With Ankylosing Spondylitis (MK-0663-163)A Nested Case-control Post-authorization Safety Study of Etoricoxib and Other Anti-inflammatory Therapies in a Cohort of Patients With Ankylosing Spondylitis (AS) in the UK, France and GermanyAnkylosing SpondylitisDrug: Etoricoxib;Drug: Other Cox-2 inhibitors;Drug: Other Non-selective NSAIDs;Other: No anti-inflammatory treatmentMerck Sharp & Dohme Corp.NULLCompletedN/AN/AAll27381N/ANULL
9EUCTR2007-007637-39-DE
(EUCTR)
17/12/200815/04/2008Effects of NSAIDs on RAdiographic Damage in AS (ENRADAS) – a prospective randomised controlled trial - Amendment 2 - ENRADASEffects of NSAIDs on RAdiographic Damage in AS (ENRADAS) – a prospective randomised controlled trial - Amendment 2 - ENRADAS Ankylosing spondylitis patients (according to mod. New York criteria) who have have active disease at inclusion defined as BASDAI question 2 (related to back pain) >= 4 (VAS, range 0-10) without NSAID treatment and with a clinical indication for NSAID therapy based on signs and symptoms.
MedDRA version: 9.1;Level: LLT;Classification code 10002556;Term: Ankylosing spondylitis
Trade Name: Voltaren resinat
Product Name: Voltaren resinat
Product Code: not applicable
Charité - Campus MitteNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
174Germany
10NCT00715091
(ClinicalTrials.gov)
September 200814/7/2008Effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) on RAdiographic Damage in Ankylosing SpondylitisEffects of NSAIDs on RAdiographic Damage in Ankylosing Spondylitis (ENRADAS) - a Prospective Randomised Controlled TrialAnkylosing SpondylitisDrug: diclophenacCharite University, Berlin, GermanyNULLCompleted18 Years65 YearsBoth180Phase 4Germany
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11EUCTR2006-002306-64-DE
(EUCTR)
28/12/200604/10/2006Open label clinical trial with Rituximab (MabThera ®) in Ankylosing Spondylitis - Extension of open label trial: Re-Treatment of patients who have shown response to first course of Rituximab - Ritux-AS-01Open label clinical trial with Rituximab (MabThera ®) in Ankylosing Spondylitis - Extension of open label trial: Re-Treatment of patients who have shown response to first course of Rituximab - Ritux-AS-01 Moderate to severe ankylosing spondylitis who have had an inadequate response to or do not tolerate conventional therapy including NSAIDs, DMARDs and TNF alpha inhibitorsTrade Name: Rituximab/ Mabthera
Product Name: MabThera
Product Code: Ro45-2294
INN or Proposed INN: rituximab
Charité UniversitaetsmedizinNULLNot RecruitingFemale: yes
Male: yes
Germany